Skip to content
Austin Top 50
Author:
UroGen Pharma Ltd.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
←
Previous Page
1
2